Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
F. Markus Leweke, Cathrin Rohleder, C.W. Gerth, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Jiangling Peng, Mingjie Fan, Chelsea An, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 130, Iss. 4, pp. 439-456
Open Access | Times Cited: 180
The therapeutic potential of purified cannabidiol
Saoirse E. O’Sullivan, Sanne Jensen, Gitte Nykjaer Nikolajsen, et al.
Journal of Cannabis Research (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 29
Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance
George Jîtcă, Bianca Eugenia Ősz, Camil-Eugen Vari, et al.
Antioxidants (2023) Vol. 12, Iss. 2, pp. 485-485
Open Access | Times Cited: 25
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Inga Dammann, Cathrin Rohleder, F. Markus Leweke
Pharmacopsychiatry (2024) Vol. 57, Iss. 03, pp. 115-132
Closed Access | Times Cited: 13
The Impact of THC and CBD in Schizophrenia: A Systematic Review
Saeed Ahmed, Robert M. Roth, Corneliu N. Stanciu, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 47
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022)
José Diogo R. Souza, Júlia Cozar Pacheco, Giordano Novak Rossi, et al.
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2598-2598
Open Access | Times Cited: 38
Cannabidiol and brain function: current knowledge and future perspectives
Moniek Schouten, Sebastiaan Dalle, Dante Mantini, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 8
CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions
Lixuan Qian, Jessica L. Beers, Klarissa D. Jackson, et al.
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 484-484
Open Access | Times Cited: 7
Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
Tibor Štark, Serena Di Martino, Filippo Drago, et al.
Pharmacological Research (2021) Vol. 174, pp. 105938-105938
Closed Access | Times Cited: 33
The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review
Petru Fabian Lungu, Corina-Miruna Lungu, Alin Ciobîcă, et al.
Brain Sciences (2024) Vol. 14, Iss. 4, pp. 359-359
Open Access | Times Cited: 4
Cannabidiol reverses myeloperoxidase hyperactivity in the prefrontal cortex and striatum, and reduces protein carbonyls in the hippocampus in a ketamine-induced schizophrenia rat model
Sofia de Almeida Queiroz, Linério Ribeiro de Novais Júnior, ANITA PACHECO, et al.
Schizophrenia Research (2025) Vol. 278, pp. 82-95
Closed Access
Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial
Ralph‐Sydney Mboumba Bouassa, Eve Comeau, Yulia Alexandrova, et al.
Cells (2023) Vol. 12, Iss. 14, pp. 1811-1811
Open Access | Times Cited: 8
Investigating Cannabidiol’s Potential as a Supplementary Treatment for Schizophrenia: A Narrative Review
Jes Sebastian Denis Völker, I. Micluția, Ramona-Cristina Vinași
European Journal of Pharmacology (2024) Vol. 979, pp. 176821-176821
Closed Access | Times Cited: 3
Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028)
Ralph‐Sydney Mboumba Bouassa, Judy Needham, Dana Nohynek, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3168-3168
Open Access | Times Cited: 12
Role of prolactin in the protective effect of amisulpride against 1,2-Diacetylbenzene’s neurotoxicity
Ngoc Minh-Hong Hoang, Hai Duc Nguyen, Wonhee Jo, et al.
Environmental Toxicology and Pharmacology (2024) Vol. 107, pp. 104418-104418
Closed Access | Times Cited: 2
Cannabidiol as an antipsychotic drug
Débora Cristina Niero Fabris, João Roberto Lisboa, Francisco Silveira Guimarães, et al.
International review of neurobiology (2024), pp. 295-317
Open Access | Times Cited: 2
Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial
T. A. Dixon, Kristin S. Cadenhead
Trials (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review
Timothy A. Couttas, Beverly Jieu, Cathrin Rohleder, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 9
A bibliometrics and visualization analysis of cannabidiol research from 2004 to 2021
Liu Liu, Jianxing Liu, Ming Zhao, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 9
Cannabinoids in the Orthopedic Setting: A Literature Review
Dominic S. Carreira, Steven Garden, Allison Huffman, et al.
Orthopedics (2022) Vol. 45, Iss. 4
Closed Access | Times Cited: 7
Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs
Adrian Andrzej Chrobak, Jarosław Woroń, Marcin Siwek
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Maternal Immune Activation and Endocannabinoid System: Focus on Two-Hit Models of Schizophrenia
Michele Santoni, Marco Pistis
Biological Psychiatry (2024)
Open Access | Times Cited: 1
Review of the Efficacy and Safety of Cannabidiol with a Focus on Children and Adolescents in the Treatment of Psychiatric Symptoms and Disorders
Amanda Sun, Aimee E. Sullivan, Jarrod M. Leffler, et al.
Adolescent Psychiatry (2023) Vol. 13, Iss. 3, pp. 143-159
Closed Access | Times Cited: 3
Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review
Garrison J. B. Dyck, Zaid H. Maayah, Dean T. Eurich, et al.
Schizophrenia Bulletin Open (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 6
Effects of the Acute and Chronic Administration of Cannabidiol on Cognition in Humans and Animals: A Systematic Review
Ana Julia de Lima Bomfim, Stefany Mirrelle Fávero Zuze, Daiene de Morais Fabrício, et al.
Cannabis and Cannabinoid Research (2023) Vol. 8, Iss. 6, pp. 955-973
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top